How Quitting Smoking Can Quickly Lower Risk Of A-Fib
Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.
Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."
"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.
The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.
"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.
The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.
Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:
1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.
2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.
3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.
4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.
5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.
6. Drinking water can help flush nicotine out of your system faster, reducing cravings.
7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.
Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.
Credit: Mark Kelly/X
Actress Olivia Munn has joined US Senator Mark Kelly to push for legislation that would make breast cancer risk assessments a routine part of healthcare for American women, helping them understand their individual risk and access appropriate screening.
Together, they have introduced the Know Your Risk Act, which aims to expand access to validated breast cancer risk assessment tools and integrate them into routine healthcare.
Munn, who was diagnosed with breast cancer in 2023, said a risk assessment prompted her doctor to recommend further testing despite her having a normal mammogram and negative genetic testing. The additional tests detected an aggressive cancer early.
"Had it not been for that assessment, my breast cancer may not have been identified when it was," Munn said while announcing the legislation alongside Kelly.
Also read: World Breast Cancer Day 2026: Life After Breast Cancer, The Fear No One Sees
Announcing the legislation outside the US Capitol, Kelly said existing breast cancer risk assessment tools are not being used widely enough, leaving many women unaware of their individual risk.
"These tools already exist, but too often doctors aren't using them and women don't know that they're available," Kelly said.
The Democratic senator from Arizona said the Act would make breast cancer risk assessments a routine part of healthcare, helping women and their doctors understand individual risk and determine appropriate screening.
"Women shouldn't have to ask for these assessments. They should be part of regular care like getting a blood pressure reading taken," Kelly said.
He added that the legislation had bipartisan support, with lawmakers recognizing the importance of expanding access to early detection.
Munn's experience highlights why individual risk assessments matter, particularly when standard screening and genetic testing may not identify a woman's breast cancer risk.
Despite having a normal mammogram and negative genetic testing, her risk assessment prompted further investigations that led to her diagnosis.
She said the experience motivated her to work with Kelly to ensure other women have access to similar assessments.
According to the World Health Organization (WHO), breast cancer caused an estimated 694,000 deaths worldwide in 2024. It was the most commonly diagnosed cancer among women in 164 of 186 countries.
In the US, breast cancer is the second leading cause of cancer death among women, according to the Centers for Disease Control and Prevention (CDC).
Early detection can significantly improve breast cancer outcomes. According to the National Cancer Institute, the five-year relative survival rate for women with localized breast cancer is more than 99%.
During the announcement, a representative of breast cancer organization Susan G. Komen highlighted the difference between detecting the disease before and after it spreads, noting that survival rates can fall to around 30% when breast cancer is diagnosed at a distant stage.
The representative also pointed to the rising number of diagnoses among women under 50, many of whom may not consider themselves at risk.
The Know Your Risk Act seeks to address this gap by expanding access to validated risk assessment tools, helping women and their doctors better understand individual risk and make informed decisions about screening.
Credit: AP Photos
After 26 years, the US has lost its measles elimination status, marking a major setback for public health efforts. The resurgence has intensified criticism of Health and Human Services Secretary Robert F. Kennedy Jr. over his vaccine policies and rhetoric.
The Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000.
The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.
A CDC-led report identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns.
The actual number may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.
“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.
Decades of MMR vaccination meant many doctors had never encountered measles during their medical careers. However, declining vaccination rates have allowed the disease to spread in under-vaccinated communities.
Criticism of Kennedy has crossed party lines. Republican Senator Bill Cassidy of Louisiana on Sunday criticised what he called a "series of failures" under Kennedy's leadership at the Department of Health and Human Services.
"This has been a failure. If I were president, I would choose someone else because there needs to be accountability for higher health care costs, more measles deaths, losing elimination status, and no progress on processed foods," Cassidy said on CBS News.
Democratic senators Angela Alsobrooks and Patty Murray have also called for Kennedy's removal.
Alsobrooks (Maryland) condemned the loss of measles elimination status and called Kennedy's tenure a disgrace. She had called for his resignation or dismissal in May 2025. Her resolution of disapproval against Kennedy now has 28 Senate co-sponsors.
Senator Richard Blumenthal (Connecticut) has demanded answers over the alleged suppression of a CDC warning about measles risks during pregnancy, while criticising the administration's vaccine policies.
Murray (Washington) has blamed Trump and Kennedy's leadership for the loss of elimination status and repeatedly called for Kennedy's removal.
Democratic governors have also blamed Kennedy for the setback. New York Governor Kathy Hochul said the loss of measles elimination status contradicted Kennedy's promise to make America healthy again.
"RFK Jr. promised to 'Make America Healthy Again.' Now America has lost its measles-free status for the first time in 26 years," Hochul said.
"A disgraceful display of incompetence from the nation's highest public health office," she added.
Pennsylvania Governor Josh Shapiro blamed vaccine misinformation and skepticism for the setback. "There is a clear line from the misinformation, vaccine skepticism, and incompetence of RFK Jr. to this devastating news and very real consequences," Shapiro said.
Kentucky Governor Andy Beshear explicitly demanded Kennedy's removal. "This dangerous setback was 100% avoidable and is the result of one person: RFK Jr.," Beshear said. "Remove him now."
An HHS spokesperson rejected the governors' criticism in a statement to Fox News Digital, calling their attacks "baseless" and arguing that declining vaccination rates predated the Trump administration.
The spokesperson said the administration remained focused on expanding vaccine access, closing immunisation gaps and assisting state and local officials with outbreak investigations.
Kennedy has vowed to stop measles outbreaks and restore the country's elimination status while continuing to recommend vaccination.
"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," Kennedy said in a statement.
"I continue to recommend MMR vaccination as the most effective way to prevent measles," he added.
Credit: AI
A schizophrenia drug has reportedly proven effective in fighting manic symptoms like hallucinations and delusions that accompany Alzheimer's disease. The finding has sparked hope to treat one of the most distressing symptoms complications of dementia.
The drug, Cobenfy (xanomeline and trospium chloride), developed by Bristol Myers Squibb (BMS), is currently being investigated for treating psychosis that patients with Alzheimer's disease may experience. The preliminary findings from two Phase 3 clinical studies showed improvements in hallucinations, delusions and the severity of the overall disease among participants who received the drug.
The findings were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. Cobenfy is currently approved in the US for schizophrenia in adults, not for Alzheimer's-induced psychosis.
Also read: Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?
The findings came from two studies within BMS's Phase 3 ADEPT clinical development programme.
In the ADEPT-1 study, 273 participants completed a 12-week treatment period in which patients knew they received Cobenfy.
Researchers observed a mean reduction of 12 points in participants' hallucination and delusion scores, which was measured using the Neuropsychiatric Inventory-Clinician (NPI-C) scale. Their overall scores of disease severity also improved.
A separate study, ADEPT-3, evaluated long-term safety and tolerability of the drug. Among 401 participants, 273 completed the 52-week treatment period. Their hallucination and delusion scores also improved.
However, these findings came from open-label treatment trials, which means that participants and researchers knew that the drug was being administered. More reliable evidence will come from the blinded parts of the ADEPT programme, which evaluate the treatment's efficacy against a control group.
Alzheimer's disease is a progressive neurological condition that damages brain cells and gradually affects memory, thinking, behaviour and the ability to perform everyday activities. Some people with Alzheimer's also develop psychosis, which can present with symptoms like hallucinations and delusions.
Hallucinations occur when someone sees, hears or experiences things that are not actually present. For instance, a person may see people around them who are not actually there or hear voices that others cannot hear.
Delusions involve strongly believing something that is not true. For example, an Alzheimer's patient with psychosis may be convinced that family members are stealing from them, that their partner is being unfaithful or that someone is trying to harm them.
According to BMS, approximately 30–50% of people with Alzheimer's experience psychosis during the course of the disease.
These symptoms can be distressing for patients as well as caregivers. Researchers also observed faster cognitive and functional decline in patients with psychosis. This increased caregiver burden and a greater likelihood of institutionalisation.
Despite the severity of Alzheimer's-induced psychosis, there are currently no FDA-approved medicines for treating it.
Cobenfy works differently from other antipsychotic medicines, which usually target dopamine receptors in the brain. Cobenfycombines two drugs: xanomeline and trospium chloride.
Xanomeline activates muscarinic receptors, specifically M1 and M4 receptors, which regulate communication between brain cells, cognition and behaviour. By targeting these receptors, xanomeline regulates parts of brain that are involved in psychiatric symptoms.
Trospium chloride is added to reduce unwanted effects of xanomeline outside the brain, especially those involving the peripheral nervous system.
In the 12-week ADEPT-1 treatment period, 56.6% of participants experienced at least one adverse event due to the drug. Serious adverse events were reported in 5% of participants, while 4.4% stopped the treatment because of side effects.
In the longer-term ADEPT-3 study, adverse events were reported in 65.1% of participants, serious adverse events in 7.7%, and discontinuations due to adverse events in 4.7%.
Cobenfy remains investigational for its use for Alzheimer's-related psychosis. The ongoing ADEPT programme includes more studies to assess its efficacy , dose and long-term safety. BMS is expected to share further findings along with important results placebo-based trials.
© $2026 Times Horizon Private Limited